^
    Back
    Association details:
    Biomarker:HLA-DRB1*01:01
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)

    Published date:
    10/09/2021
    Excerpt:
    CR was achieved in patients carrying HLA-DQB1*03:02, -DQB1*05:01, and -DRB1*01:01-class II alleles. HLA genotyping may help predict Btz-induced toxicity and treatment efficacy in patients with MM…
    DOI:
    10.1111/cas.15158